Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic lymphocytic leukemia.

Neil E Kay1, Terry J Hamblin, Diane F Jelinek

  • 1Mayo Clinic, Department of Medicine, Rochester, MN 55905, USA.

Hematology. American Society of Hematology. Education Program
|November 26, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proteomic and phosphoproteomic signatures of disease progression in unmutated IGHV chronic lymphocytic leukemia.

Clinical proteomics·2026
Same author

Sex-specific dysregulation of exosomal non-coding RNAs drives multiple myeloma progression.

Blood cancer journal·2025
Same author

Spatially defined intratumoral immune biomarkers predict recurrent versus second primary tumors in non-small cell lung cancer.

Precision clinical medicine·2025
Same author

Genomic characterization of chronic lymphocytic leukemia in patients of African ancestry.

Blood cancer journal·2025
Same author

Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912.

Blood advances·2024
Same author

Analysis of Normal Plasma Cell Distribution Across Distinct Age Cohorts Reveals Age-Dependent Changes.

The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society·2024
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

This review updates early stage B-cell chronic lymphocytic leukemia (B-CLL) management. It covers diagnosis, biology, and interventions, focusing on predicting progression and guiding treatment decisions for better patient outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Early stage B-cell chronic lymphocytic leukemia (B-CLL) requires updated management strategies.
  • Advances in understanding disease parameters necessitate refined prediction of progression and treatment needs.

Purpose of the Study:

  • To provide a comprehensive update on the diagnosis, biology, and intervention of early stage B-cell chronic lymphocytic leukemia (B-CLL).
  • To develop improved algorithms for managing early stage B-CLL by integrating new prognostic and biologic insights.

Main Methods:

  • Review of current literature on B-CLL diagnosis, including preclinical phases and prognostic features.
  • Analysis of biologic aspects such as gene expression, genetic defects, cytokines, and microenvironment interactions.
  • Evaluation of historical and current treatment approaches, including single agents, chemoimmunotherapy, stem cell transplant, and novel antibodies.

Related Experiment Videos

Main Results:

  • Identification of key diagnostic procedures and prognostic markers for predicting B-CLL progression.
  • Elucidation of biologic pathways driving B-CLL progression and potential therapeutic targets.
  • Comparison of various treatment strategies for previously untreated progressive B-CLL, including chemoimmunotherapy and newer agents.

Conclusions:

  • Accurate diagnosis and prognostic feature utilization are crucial for deciding between watchful waiting and active treatment in early stage B-CLL.
  • Understanding B-CLL biology offers opportunities for targeted therapeutic interventions even in early disease stages.
  • Integrating new biologic knowledge into management algorithms can optimize treatment decisions for B-CLL patients.